Table 1.
Clinical condition of the dogs under different therapeutic protocols at the end of the studya
| Groups | Asymptomatic | Oligosymptomatic | Symptomatic | Total of dogs alive/deadb |
|---|---|---|---|---|
| Glucantime® | 2(50%) | 2(50%) | NO | 4/2 |
| Glucantime® + Leish110f®/MPL-SE® | 3(60%) | 2(40%) | NO | 5/1 |
| Leish110f®/MPL-SE® | NO | NO | 6(100%) | 6/0 |
| MPL-SE® | NO | NO | 5(100%) | 5/1 |
| Placebo (saline) | NO | NO | 3(100%) | 3/3 |
a
Results were expressed in number of observed animals (percentage); NO: non-observed.
b
Dead animals were classified as oligosymptomatic (Glucantime® alone and Glucantime® + Leish-110f®/MPL-SE®) or symptomatic (Leish-110f®/MPL-SE®, MPL-SE® and Placebo) at the end of the study.